Editas Medicine is a clinical-stage gene editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world.

Editas is researching and developing both in vivo gene editing medicines, which edit genes inside a person’s body, and ex vivo gene editing cell medicines, where editing occurs in a person’s cells outside of their body and those edited cells are transferred back into patient’s body.

• Executing RUBY study (now considered the Phase 1/2/3 trial to support a BLA filing of reni-cel for severe sickle cell disease)
• Executing Edithal study in transfusion-dependent beta thalassemia
  
  
  

Gene Editing

Hematology